Antibodies comprising a common light chain and uses thereof
Inventors
Charpentier, Thomas • Chambers, Ross Stewart • Stafford, Lewis J. • Barnes, Trevor • Sullivan, Jonathan T.
Interested in licensing this patent?
MTEC can help explore whether this patent might be available for licensing for your application.
Assignees
MemberIntegral MolecularIntegral MolecularIntegral Molecular is a biotechnology company specializing in technologies and services for antibody discovery, engineering, and specificity testing, with a focus on membrane proteins, viruses, and related biotherapeutics. The company’s platforms support antibody development, comprehensive protein-level specificity assessment, and virology research. Integral Molecular collaborates with industry partners and regulators, and its tools have contributed to regulatory innovations, hundreds of published studies, and the advancement of new therapeutics across oncology, infectious disease, and autoimmune disorders.
Integral Molecular is a biotechnology company specializing in technologies and services for antibody discovery, engineering, and specificity testing, with a focus on membrane proteins, viruses, and related biotherapeutics. The company’s platforms support antibody development, comprehensive protein-level specificity assessment, and virology research. Integral Molecular collaborates with industry partners and regulators, and its tools have contributed to regulatory innovations, hundreds of published studies, and the advancement of new therapeutics across oncology, infectious disease, and autoimmune disorders.
Publication Number
US-12428474-B2
Publication Date
2025-09-30
Expiration Date
Abstract
Peptides and uses thereof, such as a common light chain in an antibody, are provided.
Core Innovation
The invention relates to antibody light chain variable regions defined by specific light chain CDRs (LCDR1, LCDR2, and LCDR3). The disclosed light chain variable region comprises an LCDR1 amino acid sequence, an LCDR2 amino acid sequence, and an LCDR3 amino acid sequence, each specified by SEQ ID NOs. Multiple alternative LCDR1/LCDR2/LCDR3 sets are listed, and the disclosure also describes a common light chain that can be paired with various heavy chains independent of antigen target.
In the pharmaceutical composition aspect, the invention provides a pharmaceutical composition comprising a pharmaceutically acceptable excipient and the antibody light chain variable region. The antibody light chain variable region is defined by combinations of LCDR1, LCDR2, and LCDR3 amino acid sequences using specific SEQ ID NOs, including enumerated pairings and groupings.
In the nucleic-acid aspect, the invention provides a nucleic acid encoding the antibody light chain variable region with the same SEQ ID NO-defined LCDR1, LCDR2, and LCDR3. A further disclosed embodiment includes a cell containing the nucleic acid. The disclosure also places the light chain designs within antibody composition context and references a kit for detecting a target protein using antibodies having the common light chain.
Claims Coverage
The document provides two independent claims. Both independent claims define sequence-identity-defined antibody light chain variable regions by reciting inventive features centered on specific LCDR1/LCDR2/LCDR3 amino acid sequences specified by SEQ ID NOs, with one claim directed to a pharmaceutical composition and the other directed to a nucleic acid encoding the variable region.
Pharmaceutical composition with specified LCDR combinations
A pharmaceutical composition comprising a pharmaceutically acceptable excipient and an antibody light chain variable region comprising LCDR1, LCDR2, and LCDR3, where the light chain variable region comprises one of the specified sets of LCDR1/LCDR2/LCDR3 amino acid sequences defined by SEQ ID NO combinations.
Nucleic acid encoding specified LCDR combinations
A nucleic acid encoding an antibody light chain variable region comprising LCDR1, LCDR2, and LCDR3, where the light chain variable region comprises one of the specified sets of LCDR1/LCDR2/LCDR3 amino acid sequences defined by SEQ ID NO combinations.
Across the independent claims, the main inventive coverage is the explicit definition of antibody light chain variable regions by specified LCDR1/LCDR2/LCDR3 amino acid sequence identities via SEQ ID NOs. The first independent claim applies this sequence-defined variable region within a pharmaceutical composition, and the second independent claim applies it within a nucleic acid encoding that variable region.
Stated Advantages
Not explicitly described in patent.
Documented Applications
Therapeutic use as a therapeutic antibody context is included in the disclosed antibody composition context.
A kit for detecting a target protein using antibodies with the common light chain is included.
Detection contexts are referenced, including ELISA, biosensor, sandwich assay, and flow cytometry.
Interested in licensing this patent?